Related references
Note: Only part of the references are listed.Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors
Magali Svrcek et al.
BULLETIN DU CANCER (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients
Amanda Frydendahl Boll Johansen et al.
BMC CANCER (2019)
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
Romain Cohen et al.
JAMA ONCOLOGY (2019)
The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors
Laetitia Marisa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors
Laetitia Marisa et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
Ari Vanderwalde et al.
CANCER MEDICINE (2018)
Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability
Vincent Jonchere et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2018)
Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS
Esko A. Kautto et al.
ONCOTARGET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer
Olivier Buhard et al.
JOURNAL OF MEDICAL GENETICS (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Beifang Niu et al.
BIOINFORMATICS (2014)
Microsatellite Instability Detection by Next Generation Sequencing
Stephen J. Salipante et al.
CLINICAL CHEMISTRY (2014)
Patients With Colorectal Tumors With Microsatellite Instability and Large Deletions in HSP110 T17 Have Improved Response to 5-Fluorouracil-Based Chemotherapy
Ada Collura et al.
GASTROENTEROLOGY (2014)
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
Coralie Dorard et al.
NATURE MEDICINE (2011)
Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats
J-F You et al.
BRITISH JOURNAL OF CANCER (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors
O Buhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Evaluation of tumor microsatellite instability using five quasi monomorphic mononucleotide repeats and pentaplex PCR
N Suraweera et al.
GASTROENTEROLOGY (2002)
Share Paper
